Yamamoto, Hiroyuki http://orcid.org/0000-0002-0954-6806
Arai, Hiroyuki
Oikawa, Ritsuko
Umemoto, Kumiko
Takeda, Hiroyuki
Mizukami, Takuro
Kubota, Yohei
Doi, Ayako
Horie, Yoshiki
Ogura, Takashi
Izawa, Naoki
Moore, Jay A.
Sokol, Ethan S.
Sunakawa, Yu
Article History
Accepted: 8 March 2024
First Online: 13 April 2024
Declarations
:
: No external funding was used in the preparation of this article.
: Kumiko Umemoto has received honoraria from Chugai Pharmaceutical. Naoki Izawa has recived honoraria form Chugai Pharmaceutical. Jay A. Moore and Ethan S. Sokol are employees of Foundation Medicine, Inc. and shareholders in Roche. Yu Sunakawa has recived honoraria and research funding from Chugai Pharmaceutical. Hiroyuki Yamamoto, Hiroyuki Arai, Ritsuko Oikawa, Hiroyuki Takeda, Takuro Mizukami, Yohei Kubota, Ayako Doi, Yoshiki Horie, Takashi Ogura, and Naoki Izawa have no conflicts of interest that are directly relevant to the content of this article.
: Approval for this study, including a waiver of informed consent and a Health Insurance Portability and Accountability Act waiver of authorization, was obtained from the Western Institutional Review Board (protocol #20152817). This study was also approved by the Ethics Committee of St. Marianna University School of Medicine.
: Not applicable.
: Not applicable.
: The sequencing data generated in this study are derived from clinical samples. The data supporting the findings of this study are provided within the paper and its supplementary files. All supplementary information accompanying the different analyses and figures presented in this study are provided in the ESM. Because of Health Insurance Portability and Accountability Act requirements, we are not consented to share individualized patient genomic data that contain potentially identifying or sensitive patient information. Foundation Medicine, Inc. is committed to collaborative data analysis, and we have well-established and widely utilized mechanisms by which investigators can query our core genomic database of > 600,000 de-identified sequenced cancers to obtain aggregated datasets. Requests for collaborative datashares can be made by contacting the corresponding author(s) and completing a study review committee form. Once approved, investigators are required to sign a data transfer agreement. Written proposals are considered at monthly meetings and data transfer agreements expire 18 months from execution of the agreement.
: Not applicable.
: HY designed the study, performed the analyses, and interpreted the data. RO performed the analyses and interpreted the data. YS designed the study and interpreted the data. JM and ES collected the data, performed the analyses, and interpreted the data. All authors contributed to the writing and approved the final manuscript.